New research published in the Journal of the National Comprehensive Cancer Network found that people with newly-diagnosed hormone receptor-negative, human epidermal growth factor receptor 2-positive breast cancer were more likely to receive timely, guideline-concordant treatment, and have longer survival in states that participate in Medicaid expansion under the Affordable Care Act.
The Centers for Medicare & Medicaid Services has proposed a sweeping new Advance Care Planning quality measure (MUC2025-020) that would track end-of-life care discussions for patients 18 and older.
